Takeda Enters 2009 Focused On 2010 Patent Expirations

Takeda Pharmaceuticals enters 2009 with its focus on 2010 when its pipeline of best-selling drugs begins losing patent protection. The company's actions, as expressed by its President Yasuchika Hasegawa recently, is focused on taking advantage of recent acquisitions to reshape that pipeline with a concentration on oncology drugs. Recent purchases of major foreign drug makers have been aimed at Takeda's entry into a sector of the drug market it believes holds potential. To make the move, its management style changed from conservative to an acquisition spree that has made it one of the big three in cancer drugs. (Click here for more - a subscription may be required)